hVIVO plc Strong first half performance and record orderbook

hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced a trading update for the six-month period ended 30 June 2023.

Highlights

·    First half revenue growth of 52% to £27.3 million* (H1 2022: £18.0 million)

·    EBITDA margin c.19% (H1 2022: 12.7%)

·    Net cash of £31.3 million as at 30 June 2023 (H1 2022: £15.9 million)

·    Weighted contracted orderbook of £78 million as at 30 June 2023 (30 June 2022: c.£70 million) underpins venue visibility

·    Full year revenue and EBITDA remains in line with expectations

* The Group will now report revenue excluding other income, such as R&D tax credits. Other income in H1 2023 was £1.4 million (H1 2022: £0.9 million).

Strong revenue and robust cash generation

The Group expects to report half year revenues of £27.3 million excluding other income (H1 2022: £18.0 million), a 52% increase year-on-year. This growth has been driven through the delivery of a higher number of human challenge trials with continued increases in total contract value. In addition to the revenue generated, the Group also recognised other income relating to R&D tax credits of £1.4 million (H1 2022: £0.9 million). The improved EBITDA margin of c.19% is a result of enhanced operational efficiencies and concurrent execution of multiple larger trials. The Group continues to be strongly cash generative with a cash position of £31.3 million as at 30 June 2023 (H1 2022: £15.9 million) following the payment of a £3.0 million special dividend on 9 June 2023.

Growing orderbook

As at 30 June 2023, the Group’s weighted contracted orderbook increased to £78 million (H1 2022: £70 million), an increase of 11%, underlining the continued growth in demand for human challenge trials from the global biopharma industry. Importantly, the orderbook is diversified across multiple clients, challenge agents and geographies, which provides a strong foundation for long term revenue growth.

Full year outlook

hVIVO plc is fully contracted to achieve its revenue guidance for 2023 and the Group has a record orderbook giving visibility of revenue into the second half of 2024, which will allow the management team to effectively optimise its resources, improve strategic decision making and enhance its adaptability and flexibility in managing its revenue pipeline. This coupled with its track record of excellent operational delivery provides a strong foundation for future trading.

While there have been industry wide delays in UK clinical trial approvals by the Medicines and Healthcare products Regulatory Authority (MHRA), the Board does not currently expect the MHRA delays to have a material impact on revenue. This delay in approvals has had some impact on new trials but the Company is successfully working closely with both its clients and the MHRA to ensure the timely delivery of studies and has implemented a contingency plan to mitigate any potential impact.

Based on the current guided timeline for approvals and hVIVO’s contingency plans, the Company reaffirms its guidance of £53 million in revenue for 2023 and EBITDA margins in the mid to high teens. Revenue excludes £2 million of other income, such as R&D tax credits.

Yamin ‘Mo’ Khan, Chief Executive Officer of hVIVO plc, said: “I am pleased to announce another period of excellent growth for hVIVO, delivering strong revenues, healthy EBITDA and continued cash generation. Since the end of June our weighted contracted orderbook has increased even further following the recent announcement of our new Influenza B human challenge model. This record visibility of revenue well into the second half of 2024 provides a strong basis for future trading, as well as additional flexibility and adaptability to efficiently manage our pipeline.

“I take pride in what the team has achieved and admire their determination to continue our growth path. It has also been pleasing to see a number of our clients receive positive outcomes as a result of conducting challenge trials with us. Coupled with our current track record of operational delivery, the Board is confident that the Group will achieve its full year revenue and EBITDA expectations.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO Careers – Fueling Scientific Research

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

    hVIVO plc

    Hvivo raises full year sales and earnings guidance

    The Dublin-headquartered pharmaceutical services company said it expects to generate full year sales of £55m and earnings margins of 19 per cent Hvivo, the Irish pharmaceutical services company founded by businessman Cathal Friel, has increased its sales and

    hVIVO plc

    hVIVO reports surge in half year revenues as HCTs rise

    hVIVO, formerly Open Orphan, has today reported a jump in revenues and earnings for the six months to the end of June and said its outlook for the full year was “extremely positive”. It raised its 2023 revenue

    hVIVO plc

    hVIVO plc Upgraded Full Year Revenue and EBITDA Guidance

    hVIVO plc (Euronext & LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its unaudited interim results for the six-month period ended 30 June 2023. Financial highlights ·    First half revenue growth of

    hVIVO plc

    A day in the life of a clinical trial volunteer

    What does a day look like as a clinical trial volunteer? FluCamp is a leading clinical research organization focused on studying and developing treatments for respiratory illnesses. We conduct clinical trials and recruit volunteers to contribute to medical

    hVIVO plc

    Hvivo to move to larger “state-of-the-art” facility in London

    The Dublin-headquartered pharmaceutical services company said the expanded facility would allow it to capitalise on its growing order book Hvivo, the Dublin-listed pharmaceutical services company founded by businessman Cathal Friel, has announced plans to move to a new,

    hVIVO plc

    Biotech hVIVO expanding clinical trial capacity

    The Irish-founded biotech Hvivo is expanding its operations in London to meet growing demand for its human challenge clinical trial services. Clinical-trial specialist biotech hVIVO has announced the planned expansion of its life sciences hub in Canary Wharf,

    hVIVO plc

    Hvivo plans larger London facility to meet demand

    Pharmaceutical services firm Hvivo, formerly Open Orphan, has announced plans to open a larger facility in response to the company’s growing order book. Hvivo focuses on advancing research in infectious and respiratory diseases. The new facility will be

    hVIVO plc

    hVIVO plans for a new consolidated facility in Canary Wharf, London

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its plans for a new consolidated facility at the fast-growing life sciences hub in Canary Wharf, London. The expansion,

    hVIVO plc

    hVIVO to release interim results on Tuesday 12 September 2023

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it will release its interim results for the six months ended 30 June 2023 on Tuesday 12 September

    hVIVO plc

    How our Drug Development Plan can help you get funding

    An academic spin-off biotech with only a handful of people on board was preparing for their new biological entity for clinical development. For the drug product itself, they needed to a CMC process and conduct necessary nonclinical studies.

    hVIVO plc

    VP of Clinical Operations on hVIVO’s new Facility

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

    hVIVO plc

    Developing an Influenza B Human Challenge Model

    Dr. Andrew Catchpole, Chief Scientific Officer discusses hVIVO’s bespoke human challenge model development services focusing on our most recent Flu B model. He highlights the various stages of this contract & the fundamental steps hVIVO takes to ensure

    No more posts to show